Literature DB >> 18946325

Inclusion body myositis: new insights into pathogenesis.

Michael J Garlepp1, Frank L Mastaglia.   

Abstract

PURPOSE OF REVIEW: The pathogenesis of sporadic inclusion body myositis is complex and the disease has a relentless course. Recent observations regarding possible mechanisms of disease may provide targets for therapy. RECENT
FINDINGS: Evidence is strengthening that specific T-cell and B-cell responses are ongoing in skeletal muscle in sporadic inclusion body myositis and that cytokines and chemokines generated by an autoimmune response are likely to influence antigen presentation by intramuscular dendritic cells and muscle cells, expression of amyloid precursor protein and the endoplasmic reticulum stress response. Early beta-amyloid expression and perhaps aberrant expression of protein processing enzymes, such as E3 ligases, seem to be involved in the myopathic process. NF-kappaB activation by endoplasmic reticulum stress and cytokine action further stimulates amyloid precursor protein production, exacerbates endoplasmic reticulum stress and increases myostatin content in muscle contributing to muscle atrophy.
SUMMARY: Understanding the paradoxes in sporadic inclusion body myositis is important in determining rational therapy for the disease. Amyloid precursor protein is expressed in muscle in other inflammatory muscle diseases but the cellular distribution differs and inclusions do not form so that other metabolic defects seem to be important. Intramuscular immune cells influence muscle function and viability in inclusion body myositis but immunotherapy is ineffective. A useful target for therapy may be restoration of muscle regenerating capacity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946325     DOI: 10.1097/BOR.0b013e328313644c

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  7 in total

Review 1.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.

Authors:  Cristina Sancricca; Marina Mora; Enzo Ricci; Pietro Attilio Tonali; Renato Mantegazza; Massimiliano Mirabella
Journal:  Neurol Sci       Date:  2011-06-22       Impact factor: 3.307

Review 3.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

4.  Cytotoxic aggregation and amyloid formation by the myostatin precursor protein.

Authors:  Carlene S Starck; Andrew J Sutherland-Smith
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

5.  Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab.

Authors:  Stefan Vordenbäumen; Eva Neuen-Jacob; Jutta Richter; Matthias Schneider
Journal:  Clin Rheumatol       Date:  2010-01-27       Impact factor: 2.980

6.  Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.

Authors:  Annie Hiniker; Brianne H Daniels; Han S Lee; Marta Margeta
Journal:  Acta Neuropathol Commun       Date:  2013-07-01       Impact factor: 7.801

7.  Feeder-supported in vitro exercise model using human satellite cells from patients with sporadic inclusion body myositis.

Authors:  Yuqing Li; Weijian Chen; Kazumi Ogawa; Masashi Koide; Tadahisa Takahashi; Yoshihiro Hagiwara; Eiji Itoi; Toshimi Aizawa; Masahiro Tsuchiya; Rumiko Izumi; Naoki Suzuki; Masashi Aoki; Makoto Kanzaki
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.